Medical Research News

Focus on the latest clinical studies, reports, findings, programs and standards covering a wide spectrum of medical and health issues. This section highlights research into human populations and includes information about research facilities, funding, resources and public policy.

ALS TDI Launches ALS Trial Navigator: A Revolutionary Platform to Simplify Access to Clinical Trials

ALS TDI Launches ALS Trial Navigator: A Revolutionary Platform to Simplify Access to Clinical Trials

The ALS Therapy Development Insitute (ALS TDI) has announced the beta launch of the ALS Trial Navigator. This innovative set of tools is designed to guide people with ALS and caregivers through the process of finding and understanding ALS clinical trials – with the ultimate goal of personalizing the search process and helping users make informed decisions about participation in trials. - February 29, 2024 - ALS Therapy Development Institute

IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024

IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024

IVIEW Therapeutics Inc. announces to present the positive topline result in the Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis in the upcoming 2024 ARVO (The Association for Research in Vision and Ophthalmology) national meeting in Seattle, WA. The Presentation... - February 28, 2024 - iView Therapeutics Inc.

New Research Findings Show That Life Span Can be Increased by Making Cells Less Efficient at Producing Energy

Pennington Biomedical Researchers Looking for New Ways to Improve Life Span and Health During Aging - February 23, 2024 - Pennington Biomedical Research Center

Cayman Chemical Introduces LipidLaunch™, Expands Portfolio of Lipid Nanoparticle Research Tools to Support Advances in RNA Therapies

Cayman Chemical introduces the latest addition to the company’s portfolio of lipid nanoparticle (LNP) research tools for academic, pharma, and biotech researchers worldwide. The LipidLaunch™ product line helps researchers pursue LNPs for the delivery of nucleic acid therapies in untold health applications, ranging from vaccine development to cancer and cell or gene therapies. - February 22, 2024 - Cayman Chemical Company

Researchers Combine Modern Equipment for Increased Precision in Body Composition Analysis

Pennington Biomedical Professor of Metabolism and Body Composition Dr. Steven Heymsfield is part of a team of researchers who confirm the results in the study: "Generative Deep Learning Furthers the Understanding of Local Distributions of Fat and Muscle on Body Shape and Health Using 3D Surface Scans." - February 21, 2024 - Pennington Biomedical Research Center

Pennington Biomedical's Dr. Jeffery Keller to Lead Answer ALS' Open Access Data Repository

Pennington Biomedical's Dr. Jeffery Keller has been named Principal Investigator to oversee Answer ALS' open access data repository, Neuromine. Serving as Director for Pennington Biomedical's Institute for Dementia Research and Prevention and a Professor of Aging and Neurodegeneration, Dr. Keller... - February 14, 2024 - Pennington Biomedical Research Center

Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report

Sponsor Outsourcing Dollars May Shift to Clinical Site Networks, Transforming the CRO Relationship - February 13, 2024 - Life Science Strategy Group, LLC

LogicalDOC Announces Exciting New Features in Version 8.9

LogicalDOC Announces Exciting New Features in Version 8.9

LogicalDOC, a leading provider of document management systems, is excited to announce the release of its latest version, LogicalDOC 8.9. This update brings new features and improvements designed to enhance user experience and increase productivity. In summary, the main points of the evolution of... - February 06, 2024 - LogicalDOC

Patient Experience and Satisfaction with Electronic Consent, Onboarding, and Diaries in Clinical Trials Report

New Market Research Shows Different Patient Preferences for Electronic Diaries - January 31, 2024 - Life Science Strategy Group, LLC

Huntington Study Group Announces 2024 Annual Meeting

Huntington Study Group Announces 2024 Annual Meeting

The Huntington Study Group® (HSG), together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease (HD), is pleased to announce that its annual meeting for 2024 is slated to take place from November 6-9 at the... - January 22, 2024 - Huntington Study Group

The Aesthetic Institute Announces Comprehensive Clinical Trial Programs in Advanced Aesthetic Techniques

The Aesthetic Institute Announces Comprehensive Clinical Trial Programs in Advanced Aesthetic Techniques

The Aesthetic Institute is a leading center for medical aesthetics and anti-aging medicine, founded by Dr. Adam Summers, who is ranked by Newsweek as one of the nation’s top plastic surgeons. The Institute has launched an expanded clinical trial program to test new technologies and protocols in various aesthetic treatments, such as chemical peels, laser hair removal, and laser skin resurfacing that is now open to the general public. - January 22, 2024 - The Aesthetic Institute

Impact of the In Vitro Diagnostic Regulation on Clinical Trials in the EU and CRO Outsourcing Report

IVDR Delays Driving Trial Sponsors to Actively Seek Alternative Site and CRO Outsourcing Strategies - January 17, 2024 - Life Science Strategy Group, LLC

Thrombolex, Inc. Announces the New Bashir™ .035 Endovascular Catheters

Thrombolex, Inc. Announces the New Bashir™ .035 Endovascular Catheters

Thrombolex, Inc., announces an expansion of the existing product line with the new BASHIR™ .035 and BASHIR™ S-B .035 Endovascular Catheters, which are comparable with an 0.035” guidewire. The BASHIR™ and BASHIR™ S-B Endovascular Catheters are 510(k) cleared for the treatment of acute pulmonary embolism (PE). - January 09, 2024 - Thrombolex, Inc.

TrialX Partners with The Michael J. Fox Foundation to Power Its Parkinson’s Clinical Trial Finder

TrialX Partners with The Michael J. Fox Foundation to Power Its Parkinson’s Clinical Trial Finder

To increase accessibility of information for individuals and families affected by Parkinson’s disease. - January 08, 2024 - TrialX

ZeroOutages Adds Nationally Recognized Hoag Health Network & Arizona Radiology to Their Growing List of HIPAA Regulated Satellite Internet with Integrated SD-WAN Clients

ZeroOutages Adds Nationally Recognized Hoag Health Network & Arizona Radiology to Their Growing List of HIPAA Regulated Satellite Internet with Integrated SD-WAN Clients

ZeroOutages, an industry leader in global Satellite Internet, patented SD-WAN connectivity, and security solutions, helps their healthcare clients maintain HIPAA compliance through enhanced security measures built within their WAN gateway appliances and facilitates scalable bandwidth utilization across multiple broadband providers. Their dedication to stringent HIPAA compliance is exemplified through their successful client relationships with Hoag Health Network and Arizona Diagnostic Radiology. - January 03, 2024 - ZeroOutages

ALPCO Announces the Commercial Launch of Its FDA 510(K) Cleared Calprotectin Immunoturbidimetric Assay

American Laboratory Products Company, Ltd. ("ALPCO"), a global provider of specialty diagnostic solutions, proudly announces the commercial launch of its FDA 510(k) cleared Calprotectin Immunoturbidimetric Assay, enhancing its suite of Gastrointestinal (GI) diagnostic solutions. In July... - December 19, 2023 - ALPCO

Huntington Study Group and Roche Collaborate on GENERATION HD2 Study

Huntington Study Group and Roche Collaborate on GENERATION HD2 Study

The Huntington Study Group together with its wholly-owned clinical research organization, HSG Clinical Research, Inc. (HSGCR), is pleased to announce a collaboration with Roche-Genentech to optimize our collective experiences in Huntington’s disease (HD) clinical research. Together we are... - December 13, 2023 - Huntington Study Group

QuBind.com Makes Major Strides in T-Cell Immunotherapy with Revolutionary AI Innovation

In just 18 months, the young startup QuBind.com has achieved a remarkable breakthrough in T-cell immunotherapy, developing an advanced AI stack that is set to revolutionize personalized medicine. This significant milestone, reached with predominantly bootstrap funding, support from friends, family, and a strategic investment from a handful general partners in the PE sector, underscores the company's innovative spirit and scientific prowess. - December 05, 2023 - QuBind Technologies Corp

FF Biotherapeutics Announces Search for Angel Investment to Revolutionize Immunotherapy and Vaccine Development

FF Biotherapeutics Announces Search for Angel Investment to Revolutionize Immunotherapy and Vaccine Development

FF Biotherapeutics, a pioneering biotech startup at the forefront of immunotherapy and vaccine development, today announced its active pursuit of Angel investment. This critical funding round aims to propel the development of its groundbreaking Synthetic Standardized Convalescent Plasma (SSCP) and... - November 29, 2023 - FF Biotherapeutics

Health Roads Joins Civitas Networks for Health

Health Roads Joins Civitas Networks for Health

Health Roads, a Health and Human Services Information Technology Consulting company based in Newark, CA, joins Civitas Networks for Health, a national collaborative working to use health information exchange, health data, and multi-stakeholder, cross-sector approaches to improve health. - November 17, 2023 - Health Roads, LLC

Fuzion Safety, Powered by WBAT, Partners with IMPaCT to Bring Best-In-Class Safety Management System to Healthcare Industry

Fuzion Safety, Powered by WBAT, Partners with IMPaCT to Bring Best-In-Class Safety Management System to Healthcare Industry

Fuzion Safety, powered by the WBAT platform, is proud to announce a partnership with IMPaCT to integrate IMPaCT’s game-changing web-based incident-reporting and AI-powered collaboration tools with the WBAT safety management system (SMS) to support and enhance safety in healthcare. - November 16, 2023 - WBAT Safety

T-Medical Group Acquires Telaleaf Health, a German Telemedicine Company, Expanding Its Cannabis Services

T-Medical Group Acquires Telaleaf Health, a German Telemedicine Company, Expanding Its Cannabis Services

T-Medical Group's primary focus is on providing telemedicine platforms that facilitate connections between patients and physicians on a global scale. They are committed to empowering individuals to explore and harness the natural healing properties. - November 16, 2023 - T-Medical Group

Successful Human Factors™ Unveils Services Addressing Project Delays and High FDA Failure Rates in MedTech

Successful Human Factors™ Unveils Services Addressing Project Delays and High FDA Failure Rates in MedTech

Notably, FDA data revealed alarmingly high failure rates in Human Factors (HF) submissions (as high as 96.1%). Leading the charge in optimizing HF projects in MedTech product development, Successful Human Factors™ unveils innovative, purpose-fit services. - October 25, 2023 - Successful Human Factors™

Thrombolex Announces Significant New Insights from the RESCUE Trial with the BASHIR™ Endovascular Catheter

Thrombolex Announces Significant New Insights from the RESCUE Trial with the BASHIR™ Endovascular Catheter

Thrombolex, Inc., announced never-before-reported major reductions in obstruction in all of the segmental pulmonary arteries (PA), based on independent core lab data analysis of 107 patients from 18 sites in the USA, with acute intermediate-risk pulmonary embolism (PE), using the BASHIR™ Endovascular Catheter and small doses of tPA. The RESCUE trial also showed unsurpassed efficacy and safety in this patient population compared to recently published studies with other FDA-cleared devices. - October 24, 2023 - Thrombolex, Inc.

Huntington Study Group® Observational Pilot Study Shows HSG’s myHDstory®  Platform Reaches the Unreachable

Huntington Study Group® Observational Pilot Study Shows HSG’s myHDstory® Platform Reaches the Unreachable

The Huntington Study Group® (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc. (HSGCR), a world leader in conducting clinical trials for Huntington’s disease (HD), today announces that the pilot observational study on their innovative online direct-to-patient... - October 16, 2023 - Huntington Study Group

Link Between Hormones and Brain Health: Insights from SottoPelle® Bioidentical Hormone Replacement Therapy

New Report by USA Today Explores the Link Between Hormones and Brain Health: Insights from SottoPelle® Bioidentical Hormone Replacement Therapy - October 14, 2023 - SottoPelle Therapy

Rosemarie K. Witter (RKW) Foundation, Inc. Commemorates 11th Anniversary with Fashion Extravaganza in Aid of Lupus

Rosemarie K. Witter (RKW) Foundation, Inc. Commemorates 11th Anniversary with Fashion Extravaganza in Aid of Lupus

Style with a purpose. Join Rosemarie K. Witter (RKW) Foundation, Inc. at the MWW Fashion Extravaganza Lupus Fundraiser on October 15th, 4pm-8pm, at Bayview House, Captain Bills. Let's celebrate fashion, compassion, and the fight against Lupus together. Enjoy discount coupons, exclusive perks, and a promotional bag. - October 13, 2023 - Rosemarie K. Witter Foundation, Inc.

knowRX Strengthens Platform to Support Physician Engagement in Clinical Trial Diversity

knowRX Strengthens Platform to Support Physician Engagement in Clinical Trial Diversity

knowRX, a clinical trial solutions provider, has launched an Investigator/Provider Learning Center on its PIXS™ platform, focusing on "Cultural Considerations in the Conduct of Clinical Trials." This initiative aims to educate physicians, increasing their awareness and understanding of clinical trials. The goal is to bridge gaps in patient access and awareness, particularly among underrepresented populations, aligning with recent FDA guidelines emphasizing diversity in clinical trials. - October 07, 2023 - knowRX, Inc.

GeneProof Announces Expansion of Its IVDR-Certified PCR Portfolio

GeneProof, a leader in molecular diagnostics, today announced the addition of six new IVDR-certified PCR kits to its expansive portfolio. This comes as a testament to the company’s dedication to delivering its entire portfolio of approximately 80 products as IVDR compliant by 2027. Currently,... - October 03, 2023 - ALPCO

Mark A. Cline, of Cline Realtor Group, Embarks on a Journey to Transform Lives with Asea Redox

Asea Redox is a pioneering company that specializes in cellular health and wellness products. By harnessing the power of redox signaling molecules, Asea Redox offers innovative solutions that support optimal cellular communication and regeneration, ultimately leading to improved overall well-being. - September 28, 2023 - Cline Realtor Group

Hemanext Inc. Announces Significant Milestone with FDA Marketing Authorization for Hemanext ONE®, Hemanext’s Innovative Red Blood Cell (RBC) Processing and Storage System

Hemanext Inc. Announces Significant Milestone with FDA Marketing Authorization for Hemanext ONE®, Hemanext’s Innovative Red Blood Cell (RBC) Processing and Storage System

Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food and Drug Administration (FDA). - September 21, 2023 - Hemanext

NeVa CLEAR Study Results Presented at ESMINT: Innovative Thrombectomy Device Achieves Notable First-Pass Success and Patient Outcomes

NeVa CLEAR Study Results Presented at ESMINT: Innovative Thrombectomy Device Achieves Notable First-Pass Success and Patient Outcomes

Primary results from the CLEAR Study(1) were presented at the ESMINT annual meeting in Marseille, France (4-6 September 2023), where Vesalio also announced the fifth anniversary of the international commercialization of the NeVa™ device. - September 21, 2023 - Vesalio

Alevea Mental Health Advocates for Psychedelic Therapy, Citing MAPS' Latest Research and Its Own Success with Ketamine Treatment

Alevea Mental Health Advocates for Psychedelic Therapy, Citing MAPS' Latest Research and Its Own Success with Ketamine Treatment

Alevea Mental Health fully endorses psychedelic therapy as an effective mental health treatment, following the recent publication of MAPS' Phase 3 study on MDMA-assisted therapy for PTSD. Alevea has already reported significant success in alleviating symptoms of anxiety, depression, and PTSD through its own Ketamine treatment programs. CEO Topher Bradshaw expressed astonishment at the remarkable patient improvements, particularly when other treatments had failed. - September 20, 2023 - Alevea Mental Health

DEA and Telemedicine: East Coast Telepsychiatry's Push for Modernized Rules

On September 12 and 13, 2023, the DEA discussed telemedicine regulations. East Coast Telepsychiatry's representatives, Pierre Montalvo and Dan Golden, attended in Arlington, VA. Mr. Golden emphasized the importance of telemedicine in prescribing controlled substances. The 2008 Ryan Haight Act's regulations are outdated, prompting the DEA to reconsider after receiving a record of over 38,000 complaints. - September 18, 2023 - East Coast Telepsychiatry

National Brain Tumor Society to Launch Campaigns Elevating the Necessity of Clinical Trials and Biomarker Testing Access, Guiding More Informed Treatment Decisions

Joint initiatives aim to help patients and families navigate the era of precision medicine in cancer care. - September 13, 2023 - National Brain Tumor Society

MPFI’s Wang Lab Awarded $1M Grant to Study Mechanism Behind Memory Decline in Alzheimer’s

MPFI’s Wang Lab Awarded $1M Grant to Study Mechanism Behind Memory Decline in Alzheimer’s

Memory loss is one of the most devastating effects of Alzheimer's disease, yet the mechanisms behind it remain a mystery. MPFI is working to change that through a new $1,038,819 research award from the National Institute on Aging of the NIH. - August 23, 2023 - Max Planck Florida Institute for Neuroscience

Renowned Stem Cell Expert Dr. Roddy McGee Joins Forces with GARM Clinic for Groundbreaking Collaboration in Regenerative Medicine

Renowned Stem Cell Expert Dr. Roddy McGee Joins Forces with GARM Clinic for Groundbreaking Collaboration in Regenerative Medicine

Leading the charge in regenerative medicine innovation, GARM Clinic is proud to announce a strategic partnership with the acclaimed Dr. Roddy McGee, widely recognized for his expertise in orthopedic surgery, stem cell therapeutics, the high-level care he provides to elite athletes, and his... - August 23, 2023 - GARM Clinic

Huntington Study Group Welcomes FDA Approval of New Drug for Chorea in Huntington’s Disease

Huntington Study Group Welcomes FDA Approval of New Drug for Chorea in Huntington’s Disease

The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in clinical trials for Huntington’s disease (HD), today shares that the Phase 3 pivotal KINECT®-HD study conducted by HSG in collaboration with Neurocrine Biosciences,... - August 18, 2023 - Huntington Study Group

EndoGlow Revolutionizes Fluorescence-Guided Minimally Invasive Surgery with the GreenEgg™ Fluorescent Manipulator

EndoGlow Revolutionizes Fluorescence-Guided Minimally Invasive Surgery with the GreenEgg™ Fluorescent Manipulator

EndoGlow, a pioneering medical technology company, proudly announces the launch of its breakthrough product, the GreenEgg™ fluorescent manipulator. Designed to revolutionize fluorescence-guided minimally invasive surgeries, the GreenEgg™ brings a new level of capability and innovation... - August 16, 2023 - EndoGlow

Huntington Study Group Announces Positive Topline Results for Virtual Unified Huntington’s Disease Rating Scale® (vUHDRS®) Study

Huntington Study Group Announces Positive Topline Results for Virtual Unified Huntington’s Disease Rating Scale® (vUHDRS®) Study

The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease (HD), today announces positive topline results from its Virtual Unified Huntington’s Disease Rating Scale®... - August 14, 2023 - Huntington Study Group

Neurobit Launches Neurobit HUB: A Comprehensive Tool for Streamlining Sleep and Population Health Research

Neurobit Launches Neurobit HUB: A Comprehensive Tool for Streamlining Sleep and Population Health Research

Neurobit announces the launch of Neurobit HUB, a groundbreaking AI-driven tool for sleep and population health research. Integrating 40 sleep biomarkers, 20 health AI modules, and clinically validated devices, it's designed to streamline clinical trials, foster collaboration, and accelerate discoveries. A revolutionary step in sleep science. Learn more at https://www.neurobit.com/research/hub - August 14, 2023 - neurobit

The ALS Therapy Development Institute and Unite Genomics Partner to Integrate Electronic Health Records Into the ALS Research Collaborative

The ALS Therapy Development Institute and Unite Genomics Partner to Integrate Electronic Health Records Into the ALS Research Collaborative

The ALS Therapy Development Institute (ALS TDI) is partnering with Unite Genomics, a leading healthcare data analytics company, to integrate electronic health record (EHR) data into the ALS Research Collaborative (ARC) via Unite Genomics’ state-of-the-art healthcare data access and analytics... - August 02, 2023 - ALS Therapy Development Institute

Emmanuel J. Ajala Chosen as a Lifetime Featured Member by Strathmore’s Who’s Who Worldwide

Emmanuel J. Ajala of Bronx, New York, has been chosen as a Lifetime Featured Member by Strathmore’s Who’s Who Worldwide Edition for his outstanding contributions and achievements in the field of research. About Emmanuel J. Ajala Emmanuel J. Ajala is a biomedical researcher/principal... - July 26, 2023 - Strathmore Worldwide

Huntington Study Group and CHDI Foundation Collaborate on Enroll-HD

Huntington Study Group and CHDI Foundation Collaborate on Enroll-HD

HSG Clinical Research, Inc. - the Huntington Study Group’s clinical research organization (CRO) and wholly owned subsidiary (collectively referred to here as HSG) - has begun providing CRO services for CHDI Foundation’s Enroll-HD observational study and clinical research platform in the... - July 25, 2023 - Huntington Study Group

Shark Tank's Kevin Harrington Joins Forces with GARM Clinic

Shark Tank's Kevin Harrington Joins Forces with GARM Clinic

GARM Clinic, a leading provider of Stem Cell Therapies and cutting-edge Regenerative Therapies, is thrilled to announce a groundbreaking partnership with Kevin Harrington, renowned entrepreneur and original "shark" from the hit TV series "Shark Tank." This collaboration marks a... - July 20, 2023 - GARM Clinic

Singapore MedTech Startup Launches Strategic Research Collaboration with Stanford University School of Medicine and the Veterans Affairs Palo Alto Health Care System

Singapore MedTech Startup Launches Strategic Research Collaboration with Stanford University School of Medicine and the Veterans Affairs Palo Alto Health Care System

NDR Medical Technology Pioneers Automated Needle Targeting Technology: Strategic Research Collaboration initiated with Clinicians from Stanford University School of Medicine and the Veterans Affairs Palo Alto Health Care System - July 17, 2023 - NDR Medical Technology

NDR Medical Technology’s ANT-X Granted FDA Clearance, Paving the Way for Image-Guided Surgeries

NDR Medical Technology’s ANT-X Granted FDA Clearance, Paving the Way for Image-Guided Surgeries

ANT-X is an interventional robot that leverages C-arm fluoroscopy to help clinicians achieve swift and accurate percutaneous needle placement. NDR Medical Technology, an AI-empowered interventional robotics company, today announced that the ANT-X has been granted FDA 510(k) clearance by the U.S. - July 17, 2023 - NDR Medical Technology

Paras Biopharma (Biologics CDMO) Announces Industry Leading Scale-up Development & Production Process of an “Onco-Immunology Fc-fusion Biologic”

Paras Biopharma (Biologics CDMO) Announces Industry Leading Scale-up Development & Production Process of an “Onco-Immunology Fc-fusion Biologic”

Paras Biopharma (Biologics CDMO) Finland team is pleased to announce that its extensive efforts have resulted in the successful scale-up, optimization & development of a biologically-active onco-immunology, “peptide FC-fusion” biologic. - July 12, 2023 - Paras Biopharmaceuticals Finland Oy

Hemanext Announces Membership in European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, today announced its membership in the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), the region's premier trade association for small to medium-sized companies in the pharmaceutical,... - July 05, 2023 - Hemanext

UserWise, LLC Celebrates Role in Norlase Obtaining 510(k) Clearance and CE Mark Approval

UserWise, LLC Celebrates Role in Norlase Obtaining 510(k) Clearance and CE Mark Approval

UserWise, LLC, a San Jose-based human factors consultancy, is pleased to announce its instrumental role in obtaining FDA 510(k) clearance and CE Mark approval for the Norlase ECHO™ Green Pattern Laser photocoagulator. UserWise began working with Norlase in 2018 to develop and execute the... - June 23, 2023 - UserWise, LLC

Press Releases 51 - 100 of 1,659